Curated News
By: NewsRamp Editorial Staff
March 26, 2026
Soligenix Gains EU Orphan Drug Designation for Behçet Disease Treatment
TLDR
- Soligenix gains EU orphan drug designation for dusquetide, securing up to 10 years of market exclusivity and enhancing its competitive edge in rare autoimmune treatments.
- The European Commission granted orphan designation based on EMA recommendation and Phase 2a data showing dusquetide's biological efficacy and safety for Behçet Disease treatment.
- This designation advances treatment options for Behçet Disease patients, addressing unmet medical needs in rare autoimmune conditions and improving quality of life.
- Soligenix's dusquetide receives EU orphan designation, adding to existing FDA designations as the company targets rare diseases with its innate defense regulator platform.
Impact - Why it Matters
This development matters because Behçet Disease is a rare, chronic autoimmune condition that causes painful inflammation throughout the body, significantly impacting patients' quality of life with limited treatment options. The orphan drug designation accelerates development and approval pathways, potentially bringing effective therapies to patients faster while providing market exclusivity that encourages pharmaceutical investment in rare diseases. For patients, this represents hope for better management of their condition; for investors, it signals progress in Soligenix's pipeline; and for the healthcare system, it addresses an unmet medical need in autoimmune disorders.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, has achieved a significant regulatory milestone with the European Commission granting orphan drug designation to its drug candidate dusquetide (SGX945) for treating Behçet Disease. This decision follows a positive recommendation from the European Medicines Agency and is supported by Phase 2a data showing biological efficacy and safety. The orphan designation provides up to 10 years of market exclusivity in the European Union, complementing existing FDA orphan and fast track designations, and represents a crucial step in advancing Soligenix's innate defense regulator platform targeting rare autoimmune conditions with unmet medical needs.
Soligenix's pipeline includes multiple promising therapies across two business segments. The Specialized BioTherapeutics segment focuses on HyBryte™ (SGX301) for cutaneous T-cell lymphoma, synthetic hypericin (SGX302) for psoriasis, dusquetide (SGX942) for inflammatory diseases like oral mucositis, and SGX945 for Behçet's Disease. The Public Health Solutions segment develops vaccines including RiVax® for ricin toxin, filovirus vaccines, and CiVax™ for COVID-19, utilizing the proprietary ThermoVax® heat stabilization technology with government funding from agencies like NIAID, DTRA, and BARDA.
This news was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN that provides comprehensive distribution services including wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution. BioMedWire serves as a key resource for investors and the public seeking updates on biotechnology developments, with additional information available through their website and SMS alerts. The platform's broad reach helps companies like Soligenix gain recognition and brand awareness in competitive markets.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix Gains EU Orphan Drug Designation for Behçet Disease Treatment
